Valeant Pharmaceuticals International Inc. said it completed an offering of $1 billion of 5.500% senior secured notes due Nov. 1, 2025.

The company used the net proceeds of the offering, along with cash on hand, to repurchase $1 billion of notes of its unit Valeant Pharmaceuticals International, consisting of $431.3 million of 7.000% senior notes due 2020 and $568.7 million of 6.375% senior notes due 2020 pursuant to a tender offer and to pay related fees and expenses.

The Bank of New York Mellon served as trustee and the notes collateral agents party.